16:34 , Sep 21, 2018 |  BC Week In Review  |  Company News

Celenex takeout first of several expected Amicus gene therapy deals

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
23:14 , Sep 20, 2018 |  BC Extra  |  Company News

Celenex takeout first of several planned gene therapy deals for Amicus

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
18:36 , Aug 23, 2018 |  BC Innovations  |  Emerging Company Profile

Bugs on film

Microbiome company Scioto Biosciences Inc. is turning a longstanding enemy of antibiotics developers -- biofilms -- into a delivery vehicle for probiotics. The company expects its lead candidate SB-121, an orally delivered biofilm formulation of...
20:46 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Invirsa raises $520K in seed round

Infectious disease play Invirsa Inc. (Columbus, Ohio) raised $520,000 in a seed financing led by CincyTech. Initial investor Rev1 Ventures also participated. Invirsa's lead candidate, INV-102, is in preclinical testing to treat acute conjunctivitis and...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Financial News

Milo Biotechnology completes venture financing

Milo Biotechnology LLC , Cleveland, Ohio   Business: Musculoskeletal   Date completed: 2016-09-20   Type: Venture financing   Raised: Not disclosed   Investors: JumpStart Inc.; Rev1 Ventures   Note: The amount raised is not disclosed....
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Nanoparticle-mediated co-delivery of small interfering RNA and cisplatin prodrug Engineered, self-assembling nanoparticles that co-deliver siRNA and a cisplatin prodrug could improve cancer chemotherapy response. The...
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer REV1 homolog (REV1); REV3-like catalytic subunit of DNA polymerase-z (REV3L) Mouse studies suggest that inhibitors of REV1 or REV3L could help increase the efficacy...